FDA approves Anoro Ellipta

Share this article:

 

The U.S. Food and Drug Administration have approved GlaxoSmithKline's Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.

Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist that can be used once a day, the first to combine two long-acting bronchodilators into a single inhaler. It is expected to be available in the first quarter of 2014.

 “We believe Anoro Ellipta will be an important treatment option for appropriate patients with COPD. …  This approval is a significant achievement for GSK,” said Darrell Baker, SVP & Head, GSK Global Respiratory Franchise.

Testing for Anoro Ellipta included seven clinical studies with almost 6,000 patients with COPD. 

Share this article:
close

Next Article in Products

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.